WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259

The WHO’s approval of Coartem Baby marks a historic achievement in malaria treatment for newborns and young infants, addressing a critical gap in healthcare. Developed by Novartis and Medicines for Malaria Venture, this innovative drug provides a safer, accurately dosed option, highlighting the importance of inclusive pharmaceutical innovation and collaborative efforts in global health.
Share
View Post

Novartis Pharma Exits from Pakistan – Asrar Qureshi’s Blog Post 1183

Asrar Qureshi’s Blog Post 1183 discusses Novartis Pakistan’s transfer to International Investment II Limited (IIL), emphasizing its implications for the pharmaceutical sector. While the change aims to ensure supply continuity and local management agility, there are concerns about potential risks, including access to innovative medicines and workforce stability. The deal represents a significant shift in Pakistan’s pharmaceutical landscape.
Share